These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


201 related items for PubMed ID: 14621574

  • 1. [Role of oral fluoroquinolones in patients with respiratory diseases].
    Ishida T.
    Kekkaku; 2003 Oct; 78(10):653-9. PubMed ID: 14621574
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial treatment of lower respiratory tract infections in the hospital setting.
    Grossman RF, Rotschafer JC, Tan JS.
    Am J Med; 2005 Jul; 118 Suppl 7A():29S-38S. PubMed ID: 15993675
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Prulifloxacin: a new antibacterial fluoroquinolone.
    Prats G, Rossi V, Salvatori E, Mirelis B.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):27-41. PubMed ID: 16441207
    [Abstract] [Full Text] [Related]

  • 5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P, Mandell L, Patou G, Dankner W, Tillotson G.
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [Abstract] [Full Text] [Related]

  • 9. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance.
    Ferrara AM.
    Infection; 2005 Jun; 33(3):106-14. PubMed ID: 15940410
    [Abstract] [Full Text] [Related]

  • 10. [Current antibiotics for clinical practice].
    Zimmerli W.
    Praxis (Bern 1994); 1996 Oct 01; 85(40):1240-4. PubMed ID: 8966413
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical studies of garenoxacin.
    Takagi H, Tanaka K, Tsuda H, Kobayashi H.
    Int J Antimicrob Agents; 2008 Dec 01; 32(6):468-74. PubMed ID: 18790608
    [Abstract] [Full Text] [Related]

  • 13. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA, Jones RN, Leeds JA, Denys G, Sader HS, Fritsche TR.
    J Antimicrob Chemother; 2006 May 01; 57(5):914-23. PubMed ID: 16549511
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM, Tillotson G.
    Int J Antimicrob Agents; 2008 Apr 01; 31(4):299-306. PubMed ID: 18276120
    [Abstract] [Full Text] [Related]

  • 17. Fluoroquinolones in ambulatory ENT and respiratory tract infections: rarely appropriate.
    Prescrire Int; 2003 Feb 01; 12(63):26-7. PubMed ID: 12602405
    [Abstract] [Full Text] [Related]

  • 18. Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia.
    Chang NN, Murray CK, Houck PM, Bratzler DW, Greenway C, Guglielmo BJ.
    Pharmacotherapy; 2005 Jan 01; 25(1):59-66. PubMed ID: 15767221
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment recommendations for patients with common respiratory tract infections with variables indicative of treatment failure.
    Basri RS, Weiland DA, Ledgerwood GL.
    J Fam Pract; 2008 Feb 01; 57(2 Suppl Managing):S19-23. PubMed ID: 18662525
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.